Hot Investor Mandate: USA Investment Firm Seeks Opportunities in Pre-Revenue, Early-Stage Life Science Technologies with Strong IP

20 Sep

An investment firm based in the USA has a newly established venture capital strategy, which has a specific focus in early-stage, pre-revenue biotech companies. The firm’s initial investment is usually around $500K, but the firm has invested as low as $250K and as high as $2-3M. At present, the firm is primarily looking for USA-based opportunities with a focus on the Midwest and East Coast regions.

The firm invests broadly across early-stage therapeutics, medical devices, and diagnostics. The firm is most interested in technologies with strong intellectual property. The firm is open to investing in all classes of medical devices including 510k and PMA. The firm works closely with a group of scientists who covers a wide range of expertise including cancer diagnostics, immunotherapy, diseases of the ear and eye, etc. The firm is not interested in healthcare analytics companies.

The firm is flexible and is open to working with all different kinds of management teams, though experience and a successful track record is a plus. The firm has both led and co-invested in financing rounds and seeks board representation most of the time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: